These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 9616891)

  • 41. [Clinical assessment of free serum prostate specific antigen (PSA)].
    Chautard D; Daver A; Bali B; Dardari J; Debras B; Colls P; Soret JY
    Prog Urol; 1996 Jun; 6(3):368-74. PubMed ID: 8763691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
    Yesner R; Kelly LJ; Chan YK
    Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer].
    Zenimoto M; Kita M; Arai T; Murayama T; Mori M
    Rinsho Byori; 2003 Oct; 51(10):969-73. PubMed ID: 14653195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longitudinal evaluation of prostate-specific antigen levels in a case-control study.
    De Biasi F; Londero D; Praturlon S; Di Donna A; Feruglio GA; Guerra UP
    Eur Urol; 1996; 29(2):184-8. PubMed ID: 8647144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
    Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
    Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
    Fukushima K; Satoh T; Baba S; Yamashita K
    Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
    España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
    Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
    Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA
    J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
    Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
    Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Measurement of serum PSA values by DELFIA PSA and its clinical significance on diagnosis and follow-up of prostate cancer patients].
    Kuriyama M; Esaki N; Yamada S; Ito S; Okano M; Takahashi Y; Shinoda I; Kawada Y; Ohkawa J; Miyawaki A
    Hinyokika Kiyo; 1992 Apr; 38(4):425-31. PubMed ID: 1382383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
    Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
    Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
    Tchetgen MB; Oesterling JE
    Urol Clin North Am; 1995 May; 22(2):333-44. PubMed ID: 7539179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of transurethral indwelling catheter on serum prostate-specific antigen level in benign prostatic hyperplasia.
    Batislam E; Arik AI; Karakoc A; Uygur MC; Germiyanoğlu RC; Erol D
    Urology; 1997 Jan; 49(1):50-4. PubMed ID: 9000185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer].
    Saito Y
    Nihon Rinsho; 1998 Aug; 56(8):1989-93. PubMed ID: 9750493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.